- Home
- SEVN vs MOLN Comparison
SEVN vs MOLN Comparison
Compare SEVN & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SEVN | MOLN |
|---|---|---|
| Founded | 1986 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.6M | 151.9M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SEVN | MOLN |
|---|---|---|
| Price | $8.43 | $4.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $10.50 | $8.38 |
| AVG Volume (30 Days) | ★ 82.8K | 3.1K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 13.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $29,383,000.00 | N/A |
| Revenue This Year | $27.75 | N/A |
| Revenue Next Year | $4.06 | $374.07 |
| P/E Ratio | $44.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $3.41 |
| 52 Week High | $12.85 | $5.36 |
Technical Indicators
Market Signals| Indicator | SEVN | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 53.15 |
| Support Level | $8.33 | $4.04 |
| Resistance Level | $8.83 | $4.49 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 16.67 | 83.03 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.